Bellicum Pharmaceuticals today announced it has received notification from the U.S. Food and Drug Administration outlining the criteria required for lifting the clinical hold on U.S. studies of BPX-501.
Bellicum Pharmaceuticals today announced it has received notification from the U.S. Food and Drug Administration outlining the criteria required for lifting the clinical hold on U.S. studies of BPX-501.